AcNK-Sup003

N/A

Report date: 2025/01/17 16:38:52

Base Information

Drug NameAcNK-Sup003
Drug Alias NameAcNK-Sup003
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionAnti-CD20Anti-CD19Natural killer cell replacements
TargetsB-lymphocyte antigen CD20B-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSupermAb (BeiJing) Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSupermAb (BeiJing) Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A